logo
Plus   Neg
Share
Email

Novartis: Sandoz' Biosimilar Ziextenzo Gets FDA Approval

Sandoz Inc., the generics division of Swiss drug maker Novartis AG, announced Tuesday that the US Food and Drug Administration approved its long-acting oncology supportive care biosimilar Ziextenzo (pegfilgrastim-bmez).

Ziextenzo is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy.

The FDA approval of Ziextenzo was based on analytical, preclinical and clinical research, including data from a pivotal three-way pharmacokinetics and pharmacodynamics study.

Sandoz biosimilar pegfilgrastim has been approved and marketed in Europe as Ziextenzo (pegfilgrastim) since 2018. Sandoz now intends to launch Ziextenzo in the US as soon as possible this year.

With the approval, Sandoz is the first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options. The company now has four US approved biosimilars.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT